ArticleAmerican journal of translational research2017
P2X7 receptor regulates sympathoexcitatory response in myocardial infarction rats via NF-κB and MAPK pathways.
Article in American journal of translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 6 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Retraction · 2018-09-01Error in Data · Original Data and/or Images not Provided and/or not Available · Results Not Reproducible ·
- Retracted
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have provided evidence for the regulatory effect of P2X7 receptor (P2X7R) on cardiovascular activities. Our study focused on exploring the function and fundamental mechanism of microglial P2X7R in controlling sympathoexcitatory response using rats with acute myocardial infarction (AMI). Coronary artery ligation was used in rats to cause AMI. And before that, rats were administrated with P2X7R siRNA that targeted P2X7R mRNA into paraventricular nucleus (PVN) or BBG (Brilliant Blue G, a P2X7 receptor antagonist). Increased expression levels of P2X7R and adenosine triphosphate (ATP) were observed in the hypothalamic PVN of AMI rats. Moreover, the knockdown of P2X7R expression by P2X7-siRNA or suppression of P2X7 receptor by BBG attenuated the elevation of both vasopressin and oxytocin levels in the PVNs of AMI rats. There was also a decrease in renal sympathetic nerve activity (RSNA) by P2X7-siRNA and BBG. Besides, inflammation was alleviated by P2X7-siRNA and BBG through suppressing pro-inflammatory cytokines IL-1β and IL-6 in PVN of AMI rats. Furthermore, blockade of P2X7R moderated the process of cardiac remodeling. This was achieved due to the regulatory effect of P2X7R on sympathoexcitatory response by influencing NF-κB and mitogen-activated protein kinase (MAPK) signaling. These findings suggest that P2X7R can act as a new regulator of sympathoexcitatory response via NF-κB and MAPK signaling pathways in AMI rats.
Indexed as
Identifiers
29218093PMC5714779W3014096779What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.